A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 16, Issue 6, 2016, Pages 679-683

  Tsai, Her Hsin ^a   Black, Christopher ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

cost effectiveness; inflammatory bowel disease; ulcerative colitis; Vedolizumab

Indexed keywords

ADALIMUMAB; GOLIMUMAB; INFLIXIMAB; VEDOLIZUMAB; GASTROINTESTINAL AGENT; INTEGRIN; INTEGRIN ALPHA4BETA7; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HUMAN; INTENTION TO TREAT ANALYSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT INDICATION; ULCERATIVE COLITIS; UNITED KINGDOM; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; COST BENEFIT ANALYSIS; ECONOMICS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; GASTROINTESTINAL AGENTS; HUMANS; INTEGRINS; SEVERITY OF ILLNESS INDEX; UNITED KINGDOM;

EID: 84992220759     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1080/14737167.2016.1246186     Document Type: Article

References (17)

1. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease:report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(SupplA):5A–36. PMID:16151544.
2. Burisch J, Pedersen N, Čuković-Čavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe:the ECCO-EpiCom inception cohort. Gut. 2014;63(4):588–597. PMID:23604131.
3. Ghosh S, Mitchell R., Impact of inflammatory bowel disease on quality of life:results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohn’s Colitis. 2007;1:10–20.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462–2476.
5. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257-65.e1-3. Epub 2011 Nov 4. DOI:10.1053/j.gastro.2011.10.032
6. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):85–95. quiz e14-5. Epub 2013 Jun 2. DOI:10.1053/j.gastro.2013.05.048
7. Lobatón T, Vermeire S, van Assche G, et al. Review article:anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(6):579–594.
8. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
9. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(23):2183–2196.
10. Wilson M, Kerrigan M, Smyth M, et al. Cost-effectiveness of vedolizumab compared with conventional therapy for treatment of moderately-to-severely active ulcerative colitis in the United Kingdom. United European Gastroenterol J. 2015 Oct;3(5 Suppl):146–687. DOI:10.1177/2050640615601623.
11. Wilson M, Kerrigan M, Smyth M, et al. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab for treatment of moderately-to-severely active ulcerative colitis in the United Kingdom. United European Gastroenterol J. 2015 Oct;3(5 Suppl):146–687. DOI:10.1177/2050640615601623.
12. Essat M, Tappenden P, Ren S, et al. Vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis:a single technology appraisal. School of Health and Related Research (ScHARR); Pharmacoeconomics. 2016 Mar;34(3):245-257. doi:10.1007/s40273-015-0334-3.
13. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342). London:National Institute of Health and Care Excellence (NICE); 2015.
14. Tsai HH, Punekar YS, Morris J, et al. A model of the long-term cost-effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008;28:1230–1239.
15. Vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio®) SMC No. (1045/15). Scottish Medicines Consortium (SMC); 2015.
16. Cost-effectiveness of vedolizumab (Entyvio®) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF-α) antagonist. Ireland:National Centre for Pharmacoeconomics (NCPE); 2015.
17. Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastro. 2016;3:e000093. DOI:10.1136/bmjgast-2016-000093.